Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SPHK1 | Q9NYA1 | 4/20 | 0.35 |
| ▸ | SLC7A5 | Q01650 | 2/20 | 0.33 |
| ▸ | CTSC | P53634 | 1/20 | 0.31 |
| ▸ | GABRP | O00591 | 2/20 | 0.30 |
| ▸ | GABRD | O14764 | 2/20 | 0.30 |
| ▸ | GABRA1 | P14867 | 2/20 | 0.30 |
| ▸ | GABRB1 | P18505 | 2/20 | 0.30 |
| ▸ | GABRG2 | P18507 | 2/20 | 0.30 |
| ▸ | GABRB3 | P28472 | 2/20 | 0.30 |
| ▸ | GABRA5 | P31644 | 2/20 | 0.30 |
| ▸ | GABRA3 | P34903 | 2/20 | 0.30 |
| ▸ | GABRA2 | P47869 | 2/20 | 0.30 |
| ▸ | GABRB2 | P47870 | 2/20 | 0.30 |
| ▸ | GABRA4 | P48169 | 2/20 | 0.30 |
| ▸ | GABRE | P78334 | 2/20 | 0.30 |
| ▸ | GABRA6 | Q16445 | 2/20 | 0.30 |
| ▸ | GABRG1 | Q8N1C3 | 2/20 | 0.30 |
| ▸ | GABRG3 | Q99928 | 2/20 | 0.30 |
| ▸ | GABRQ | Q9UN88 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7100933 | 0.87 | SLC7A5 (0.38) | SPHK1SLC7A5CTSCGABRPGABRD | |
| SCHEMBL7100924 | 0.87 | SLC7A5 (0.38) | SPHK1SLC7A5CTSCGABRPGABRD | |
| SCHEMBL5484014 | 0.77 | — | — | |
| SCHEMBL24205845 | 0.75 | — | — | |
| SCHEMBL16359889 | 0.75 | — | — | |
| SCHEMBL21345876 | 0.75 | — | — | |
| SCHEMBL23157074 | 0.75 | — | — | |
| SCHEMBL13175735 | 0.75 | — | — | |
| SCHEMBL25415648 | 0.74 | PLOD2 (0.38) | — | |
| SCHEMBL25415650 | 0.74 | PLOD2 (0.38) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8980311-B2 | Liposome-mediated ligation | UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. (US) | 2015-03-17 | — | — | US | disclosed |
| US-20090196916-A1 | Chemoselective ligation of hydrophobic reactants in a lipid phase; thioester and cysteine moieties that are involved in the ligation reaction are positioned within the lipid phase such that the ligation reaction takes place within the lipidic structure | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2009-08-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090196916-A1 | Chemoselective ligation of hydrophobic reactants in a lipid phase; thioester and cysteine moieties that are involved in the ligation reaction are positioned within the lipid phase such that the ligation reaction takes place within the lipidic structure | LIPA, LYPLA1, LYPLA2 | SPHK1 1615/4885SLC7A5 1432/4885CTSC 2163/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.